Shares of Trius Therapeutics (TSRX) shoot 8.4% higher in premarket action after the firm...

|By:, SA News Editor

Shares of Trius Therapeutics (TSRX) shoot 8.4% higher in premarket action after the firm announces positive results from its first Phase 3 trial for its tedizolid treatment for acute bacterial skin and skin structure infections.